EUCTR2014-004473-16-CZ进行中（未招募）1 期
Prospective study investigating efficacy of lanreotide on decrease of chemotherapy induced diarrhoea (CID) in patiens with colorectal carcinoma. - STOPRHEA
Masarykuv onkologický ústav0 个研究点目标入组 60 人开始时间: 2016年3月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1Pacient with histologically verified colorectal carcinoma.
- •2Pacient treated by chemotherapy based on 5-FU, capecitabine or irinotecan in adjuvant or paliative indication. This includes regimens: FUFA Mayo, FUFA DeGramont, FOLFOX, FOLFIRI, bolus regimens with 5-FU and oxaliplatine or irinotecan, monotherapy by 5-FU, capecitabine or irinotecan. Combination of chemotherapy and targeted therapy is allowed (bevacizumab, cetuximab, panitumumab).
- •3Patients with CID grade =3 according the CTCAE classification version 4.03 (increase of number of stools of more than 7 per day against the entry state, incontinence, if the diarrhoea and its complications are the reason for hospitalisation, significant increase of bowel movements by colonostomy against the entry state, diarrhoea inducing limitation of independence in common everyday activities).
- •Note: Patients with colonostomy who receive enteral alimentation can be enrolled.
- •4CID resistant to diet and common medication which should include loperamide. This resistance is defined as a persisting diarrhoea grade =3 after 24-hours treatment by loperamide, the maximum dose allowed 8cps/day. In the first treatment line of CID also other common medication can be used (diphenoxylate, atropine, carbo medicinalis).
- •5Age =18 years and =80 years.
- •6Patients with PS WHO =3 with anticipated survival at least 3 months.
- •7Patients understands the informed consent and signs it.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1CID during concomitant chemoradiotherapy.
- •2Somatostatine analogs used for treatment of the current CID. Previous medication by short-acting somatostatine analogs or long-acting somatostatine analogs is allowed.
- •3Patients with proven or suspected chronic irradiation enteritis.
- •4Known allergy to Somatuline Autogel 60mg, 90mg or 120mg nor another somatostatine analogs.
- •5Anamnesis of acute or chronic enteritis, malabsorption syndrome or idiopatic bowel inflammation (Crohn's disease, ulcerative collitis).
- •6Bowel fistula, short bowel syndrome.
- •7Anamnesis of cholecystitis in cholecystolithiasis, if cholecystectomy have not been performed.
- •8Serious hepatic disease. Values of liver function parameters (bilirubin, ALT, AST, GGT, ALP) >3 fold of maximum normal values.
- •9Diarrhoea (= grade 2) or bowel incontinence from another reasons than CID (e.g. epidemiological anamnesis, dietary error).
- •10Pregnancy or breastfeeding (exluded by anamnesis)
- •11Patients who participated in some other clinical study - during 30 days prior to screening.
研究者
相似试验
招募中
1 期
Prospective study to evaluate the efficacy of letermovir prophylaxis for the prevention of CMV infection in lung transplant recipients compared to a retrospective cohort treated with standard valganciclovir prophylaxis for 12 months (LETERCOR Study).lung transplant patients (D+/R-)CTIS2023-504384-16-00Fundacion Para La Investigacion Biomedica De Cordoba70
招募中
不适用
A clinical study evaluating the effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infectiorecurrent urinary tract infectionJPRN-UMIN000015476Okayama University Medical School of Medicine, Dentistry and Pharmaceutical Sciences20
进行中（未招募）
1 期
Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccinatioThe study will be conducted in non-oncological female patients older than 50 years who have received the first dose of a COVID vaccination, or who have received the full vaccination within 8 weeks prior to the first planned blood collection.MedDRA version: 23.1Level: PTClassification code 10084457Term: COVID-19 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-002476-39-ITDOMPé FARMACEUTICI S.P.A.40
已完成
不适用
A multicenter clinical trial of the effect of raloxifene hydrochloride for the prevention of health care problems caused by bilateral oophorectomy due to endometrial cancerJPRN-UMIN000013039Osaka University Graduate School of Medicine, Department of Obstetrics and Gynecology200
已完成
4 期
A study evaluating the therapeutic potential of low dose Roxithromycin therapy in patients of stable bronchial asthma.CTRI/2009/091/000109Cipla India Ltd